Posttest risk calculation following positive noninvasive prenatal screening using cell-free DNA in maternal plasma

详细信息    查看全文

• 作者：Peter Benn ; PhD ; DSc ; ^{benn@nso1.uchc.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：cytogenetic abnormalities ; noninvasive prenatal screening ; positive predictive value ; prenatal screening ; risk calculation ; sensitivity ; specificity
• 刊名：American Journal of Obstetrics and Gynecology
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：214
• 期：6
• 页码：676.e1-676.e7
• 全文大小：237 K

文摘

Noninvasive prenatal screening (NIPS) for fetal chromosome defects has high sensitivity and specificity but is not fully diagnostic. In response to a desire to provide more information to individual women with positive NIPS results, 2 online calculators have been developed to calculate posttest risk (PTR). Use of these calculators is critically reviewed. There is a mathematically dictated requirement for a precise estimate for the specificity to provide an accurate PTR. This is illustrated by showing that a 0.1% decrease in the value for specificities for trisomies 21, 18, and 13 can reduce the PTR from 79-64% for trisomy 21, 39-27% for trisomy 18, and 21-13% for trisomy 13, respectively. Use of the calculators assumes that sensitivity and specificity are constant for all women receiving the test but there is evidence that discordancy between screening results and true fetal karyotype is more common for older women. Use of an appropriate value for the prior risk is also important and for rare disorders there is considerable uncertainty regarding prevalence. For example, commonly used rates for trisomy 13, monosomy-X, triploidy, and 22q11.2 deletion syndrome can vary by >4-fold and this can translate into large differences in PTR. When screening for rare disorders, it may not be possible to provide a reliable PTR if there is uncertainty over the false-positive rate and/or prevalence. These limitations, per se, do not negate the value of screening for rare conditions. However, counselors need to carefully weigh the validity of PTR before presenting them to patients. Additional epidemiologic and NIPS outcome data are needed.